Over 2000 children with cancer have been enrolled across Australia since 2017. ZERO has undergone a significant expansion and now all children diagnosed with cancer in Australia have access to precision medicine.
Involving all paediatric oncology units across Australia, as well as over 22 national and international research partners, ZERO provides in-depth genomic analysis for each child enrolled, with the aims to improve survival, reduce side effects, and advance science’s understanding of childhood cancer for the benefit of all.
2000+
children enrolled
71%
recommended personalised
treatment plan
4 weeks
average turnaround time
Get Involved
Donate
Make a donation to support this world-leading precision medicine program for children with cancer.
Capacity Campaign
The capacity campaign is a landmark campaign which harnesses the very best of philanthropic Australia.
Virtual Lab Tour
Discover the research that underpins the Program by taking a virtual tour of the labs of Children's Cancer Institute.
Information for families
When a child is diagnosed with cancer, it has a devastating impact on the whole family. If you have questions about the Zero Childhood Cancer Program and how it might help your child, please read on.
Information for researchers
The Zero Childhood Cancer Program harnesses the latest technology and innovations in research to offer a truly unique insight into an individual child’s cancer to enable identification of the treatment most likely to be effective.
Information for clinicians
The Zero Childhood Cancer Program involves all major paediatric oncology units across Australia who treat the approximately 1,000 children diagnosed with cancer each year. Find out how to get involved in this life-saving program.
News and updates
World-first study into precision medicine for high-risk chil...
Precision medicine now available to all children with cancer...
ZERO enrols 1000th child – a milestone in Australia’s me...
Get in touch
Want to know more about the Zero Childhood Cancer Program? Please contact us.
